Infliximab for Treatment of Granulomatous Disease in Patients with Common Variable Immunodeficiency
- 27 July 2014
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 34 (7) , 820-827
Abstract
Eight to 22 % of common variable immunodeficiency (CVID) patients exhibit granulomas of the lungs, spleen, liver, and/or skin. Granulomas can be the most medically significant day-to-day problem for CVID patients. Currently, there are limited options for treatment of granulomas associated with CVID.Keywords
This publication has 34 references indexed in Scilit:
- Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and PermeabilityThe Journal of Immunology, 2012
- Morbidity and mortality in common variable immune deficiency over 4 decadesBlood, 2012
- How I treat common variable immune deficiencyBlood, 2010
- Common variable immunodeficiency and granulomatosis treated with infliximabClinical Immunology, 2010
- Granulomatous disease in common variable immunodeficiencyClinical Immunology, 2009
- Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromesBlood, 2009
- Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literatureAnnals of Allergy, Asthma & Immunology, 2005
- Common variable immunodeficiency treated with a recombinant human IgG, tumour necrosis factor-α receptor fusion proteinBritish Journal of Dermatology, 2001
- Noncaseating Granulomatous Disease in Common Variable ImmunodeficiencySouthern Medical Journal, 2000
- Raised serum levels of CD8, CD25 and β2-microglobulin in common variable immunodeficiencyClinical and Experimental Immunology, 1991